Articles

FDA Continuous Manufacturing: Key Insights on Drug Quality & Supply Chain

Explore the FDA's continuous manufacturing approach, focusing on improving drug quality and ensuring a resilient supply chain for critical medications like Lipitor.

FDA Real-World Evidence: Transforming US Drug Development Strategies

Discover the impact of FDA real-world evidence on US drug development strategies, particularly in advancing treatments for chronic pain and improving patient outcomes.

Diversity in Clinical Trials: FDA's New Guidance and Early Impact

This article discusses the FDA's recent guidance on increasing diversity in clinical trials and its early impact on drug development for chronic diseases.

FDA Project Frontrunner Initiative: What Companies Must Know

The FDA Project Frontrunner Initiative aims to streamline the development of Alzheimer's drugs, providing essential guidance for pharmaceutical companies navigating this evolving landscape.

FDA Accelerated Approval Oncology: 2026 Trends & Market Access Impact

This article delves into the 2026 trends in FDA accelerated approval for oncology drugs, highlighting their implications for market access and patient care.

FDA Guidelines for Clinical Trial Sites: What You Need to Know

Learn the essential FDA guidelines for clinical trial sites to ensure compliance and optimize the success of your clinical trials involving DrugX for ConditionY.

US Oncology Biosimilar Landscape 2026: Pricing & Market Access Insights

Delve into the evolving US oncology biosimilar market by 2026, analyzing pricing strategies and market access for critical treatments like Trastuzumab.

Rise of Biosimilars: Market Impact Post-2026 Patent Expirations in US

As key biologics like Herceptin face patent expirations post-2026, the rise of biosimilars is set to transform the US pharmaceutical landscape.

ANVISA Approval Insights: Impact of New Drug on Brazil's Pharma Market

ANVISA's recent approval of DrugX for treating condition Y is set to significantly influence Brazil's pharmaceutical market dynamics and patient access.

ANVISA Guidelines for Antibody-Drug Conjugates: What You Need to Know

Learn about ANVISA's essential guidelines for antibody-drug conjugates, including safety, efficacy, and regulatory requirements for effective cancer therapies.

Dubai Science Park Phase I Studies: What You Need to Know

Discover the key insights from Dubai Science Park Phase I studies, focusing on groundbreaking drugs aimed at treating chronic diseases effectively.

SAHPRA Accelerated Review Program: One Year Assessment & Oncology Approval Trends

This article assesses the first year of SAHPRA's Accelerated Review Program, focusing on oncology drug approvals and emerging trends in the pharmaceutical landscape.

Antibody-Drug Conjugates MEA: Pricing, Access & Adoption Insights 2024

This article delves into the pricing, access, and adoption trends of Antibody-Drug Conjugates in the MEA region, highlighting their role in cancer therapy for 2024.

African Medicines Agency progress: Unlocking Africa's $40B Pharma Market

The African Medicines Agency is pivotal in advancing regulatory frameworks, enhancing access to vital medicines, and unlocking Africa's $40B pharmaceutical market.

SAHPRA HIV treatment approval: Lenacapavir's Role in Epidemic Control

SAHPRA's recent approval of Lenacapavir marks a significant advancement in HIV treatment, offering new hope for epidemic control and patient care.

COFEPRIS Biocomparables Pathway: What You Need to Know

Learn about the COFEPRIS Biocomparables pathway, a crucial process for approving biosimilars like Adalimumab, aimed at enhancing treatment accessibility.

FDA Safety Labeling Changes: Impact on Antidepressant Market & Prescribing Trends 2026

This article examines the FDA's safety labeling changes for antidepressants and their potential effects on market dynamics and prescribing practices by 2026.

FDA Accelerated Approvals 2026: Zongertinib and Oncology Policy Shifts

This article delves into the FDA's 2026 accelerated approvals, focusing on Zongertinib's role in oncology and the evolving landscape of cancer treatment policies.

African Medicines Agency Impact: Multi-Regional Clinical Trials First Year Review

This article reviews the first year of the African Medicines Agency, highlighting its role in streamlining multi-regional clinical trials for malaria drugs.

UAE Cancer Clinical Trials: Middle East Oncology Hub Analysis 2024

This article analyzes the UAE's role as a leading oncology hub in 2024, highlighting key cancer clinical trials and advancements in treatments like Pembrolizumab.